Cost-Savings Associated with Multi-Disciplinary Team Approach for Reducing Macrovascular and Microvascular Complications in Patients with Type 2 Diabetes: A Predictive Model.

Abdulmajeed Alshowair, Saleh Altamimi, Faisal A Alruhaimi, Saad Alshahrani, Fatima Alsuwailem, Mona Alkhaldi, Haiam Abdalla, Fahad Hamad Alkhuraiji, Montaser Saad Alaqeel, Salman Sulaiman Almureef, Salman Alhawasy, Amro Abdel-Azeem
Author Information
  1. Abdulmajeed Alshowair: Community Health Excellence, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia. ORCID
  2. Saleh Altamimi: Community Health Excellence, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
  3. Faisal A Alruhaimi: Community Health Excellence, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
  4. Saad Alshahrani: Academic and Training Affairs, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia. ORCID
  5. Fatima Alsuwailem: Population Health Management and Research, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
  6. Mona Alkhaldi: Health Administration Office, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
  7. Haiam Abdalla: Model of Care, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
  8. Fahad Hamad Alkhuraiji: Financial Affairs, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
  9. Montaser Saad Alaqeel: Financial Affairs, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
  10. Salman Sulaiman Almureef: Cost Department, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
  11. Salman Alhawasy: Reporting Department, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
  12. Amro Abdel-Azeem: Population Health Management and Research, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia. ORCID

Abstract

Purpose: This study aims to predict the expected cost savings associated with implementing a multidisciplinary team (MDT) approach to reduce macrovascular and microvascular complications among patients with type 2 diabetes mellitus (T2DM).
Methods: This economic evaluation study was conducted in Riyadh First Health Cluster, Saudi Arabia as a predictive model conceptualized by the authors based on models used in previous studies, particularly the CORE Diabetes Model. Our model was designed based on 1) the level of glycemic control among 24,755 T2DM patients served by MDTs; 2) the expected incidence of diabetes-related complications without intervention; 3) the predicted risk reduction of developing diabetes-related complications with MDTs. Costs of complications and cost savings were then calculated and expressed as mean incremental annual cost savings adjusted for a 1% reduction in HbA1c, and a 10 mmHg reduction in systolic blood pressure (SBP).
Results: Along with the expected reduction in all diabetes-related complications, the average incremental cost savings per diabetic patient is predicted to be ($38,878) with approximately ($11,108) in the year of complication onset and ($27,770) over the subsequent post-index 10-years. On adjustment of cost savings, the average incremental cost savings are predicted to be ($22,869) for each 1% reduction in HbA1c per diabetic patient and ($27,770) for every 10 mmHg reduction in SBP per diabetic patient.
Conclusion: MDT as a model of care is effective in glycemic control among T2DM patients with a predicted significant reduction of all diabetes-related complications and in turn, a predicted significant cost savings.

Keywords

References

  1. Diabetes Ther. 2019 Apr;10(2):575-585 [PMID: 30737674]
  2. J Diabetes Res. 2021 Jul 24;2021:8866126 [PMID: 34350296]
  3. Diabetes Res Clin Pract. 2016 Oct;120:142-8 [PMID: 27552073]
  4. J Prim Care Community Health. 2023 Jan-Dec;14:21501319231204592 [PMID: 37902553]
  5. Int J Psychiatry Med. 2019 Mar;54(2):97-114 [PMID: 30114958]
  6. Diabet Med. 2023 Sep;40(9):e15074 [PMID: 36815284]
  7. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S5-26 [PMID: 15324513]
  8. Diabetes Ther. 2021 Apr;12(4):1193-1207 [PMID: 33694092]
  9. J Diabetes Res. 2019 Dec 21;2019:9325146 [PMID: 31934593]
  10. Diabetes Care. 2018 May;41(5):917-928 [PMID: 29567642]
  11. J Prim Care Community Health. 2019 Jan-Dec;10:2150132719880638 [PMID: 31631765]
  12. Diabetes Care. 2018 Jan;41(1):49-59 [PMID: 29138274]
  13. Diabetes Res Clin Pract. 2016 Apr;114:75-82 [PMID: 26809904]
  14. BMC Endocr Disord. 2018 Sep 10;18(1):62 [PMID: 30200959]
  15. Clinicoecon Outcomes Res. 2020 Aug 10;12:423-434 [PMID: 32848433]
  16. Diabetes Ther. 2021 Jun;12(6):1631-1659 [PMID: 33942247]
  17. Prim Care Diabetes. 2020 Oct;14(5):431-434 [PMID: 31902582]
  18. PLoS One. 2021 Mar 18;16(3):e0248762 [PMID: 33735275]
  19. BMC Fam Pract. 2018 Jan 2;19(1):1 [PMID: 29291706]
  20. World J Diabetes. 2019 Mar 15;10(3):140-153 [PMID: 30891150]
  21. Am J Manag Care. 2020 Jun 1;26(6):e166-e171 [PMID: 32549065]
  22. Diabetes Ther. 2017 Jun;8(3):555-571 [PMID: 28361464]
  23. BMJ Open Qual. 2023 Apr;12(2): [PMID: 37012002]
  24. Curr Med Res Opin. 2016 Jul;32(7):1243-52 [PMID: 26986190]
  25. BMC Fam Pract. 2013 Apr 04;14:45 [PMID: 23557482]
  26. BMJ. 2000 Aug 12;321(7258):412-9 [PMID: 10938049]
  27. Lancet Diabetes Endocrinol. 2021 Apr;9(4):203-211 [PMID: 33636102]
  28. Br J Gen Pract. 2018 Aug;68(673):e531-e540 [PMID: 30012812]
  29. Diabetes Res Clin Pract. 2022 Jan;183:109119 [PMID: 34879977]
  30. Diabetes Ther. 2018 Feb;9(1):87-99 [PMID: 29204855]
  31. Curr Diabetes Rev. 2017;13(1):59-64 [PMID: 26813972]
  32. J Family Community Med. 2013 Jan;20(1):1-7 [PMID: 23723724]
  33. Ann Fam Med. 2015 Nov;13(6):523-8 [PMID: 26553891]
  34. Diabetes Metab Syndr. 2019 Jan - Feb;13(1):484-491 [PMID: 30641750]
  35. Cardiovasc Diabetol. 2021 Jan 7;20(1):9 [PMID: 33413392]
  36. Diabetes Metab Syndr Obes. 2019 Oct 21;12:2193-2200 [PMID: 31695462]
  37. J Diabetes Complications. 2015 Mar;29(2):212-7 [PMID: 25498300]
  38. Diabetes Care. 2020 Jul;43(7):1557-1592 [PMID: 33534729]
  39. Am J Med. 2014 Oct;127(10 Suppl):S17-24 [PMID: 25282009]
  40. BMJ. 2000 Aug 12;321(7258):405-12 [PMID: 10938048]
  41. Diabetes Metab Syndr Obes. 2020 Nov 10;13:4249-4260 [PMID: 33204131]
  42. PLoS One. 2022 Oct 20;17(10):e0273836 [PMID: 36264903]
  43. Curr Diab Rep. 2019 May 16;19(6):34 [PMID: 31098775]
  44. BMJ Open. 2019 Jan 15;9(1):e024963 [PMID: 30782746]
  45. Cureus. 2022 Dec 5;14(12):e32221 [PMID: 36620825]
  46. BMC Endocr Disord. 2022 Nov 2;22(1):266 [PMID: 36319996]

Word Cloud

Created with Highcharts 10.0.0costsavingscomplicationsreductionpredicted2modeldiabetes-relatedexpectedamongpatientsT2DMincrementalperdiabeticpatientstudyteamMDTtypediabetespredictivebasedModelglycemiccontrolMDTs1%HbA1c10mmHgSBPaverage$27770significantPurpose:aimspredictassociatedimplementingmultidisciplinaryapproachreducemacrovascularmicrovascularmellitusMethods:economicevaluationconductedRiyadhFirstHealthClusterSaudiArabiaconceptualizedauthorsmodelsusedpreviousstudiesparticularlyCOREDiabetesdesigned1level24755servedincidencewithoutintervention3riskdevelopingCostscalculatedexpressedmeanannualadjustedsystolicbloodpressureResults:Along$38878approximately$11108yearcomplicationonsetsubsequentpost-index10-yearsadjustment$22869everyConclusion:careeffectiveturnCost-SavingsAssociatedMulti-DisciplinaryTeamApproachReducingMacrovascularMicrovascularComplicationsPatientsTypeDiabetes:Predictivecost-savingsmulti-disciplinary

Similar Articles

Cited By